Indian Union Minister Piyush Goyal has issued a strategic call to action for the domestic pharmaceutical industry, emphasizing the urgent need to scale investment in research and development and clinical trials. The minister highlighted that shifting focus toward innovation and patent acquisition is essential for Indian firms to move up the global value chain.
Addressing the need for structural stability, Goyal underscored the importance of diversifying supply chains to mitigate risks associated with over-reliance on single-source markets. For institutional investors and private equity firms, this policy stance signals a government push toward localizing high-value manufacturing and supporting the integration of global regulatory standards.
Goyal further identified the Ayush sector and medical devices manufacturing as high-growth areas ripe for capital allocation. By aligning production with international quality benchmarks, the government aims to position these segments as hubs for global export, presenting new opportunities for venture capital and private market investors looking to capitalize on India’s healthcare infrastructure expansion.
About the Author
